8-K

United States
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 27, 2007

OXiGENE, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other
jurisdiction of
incorporation) 0-21990
(Commission File
Number) 13-3679168
(I.R.S. Employer
Identification No.)

230 Third Ave, Waltham, MA 02451
(Address of principal executive offices)

Registrant’s telephone number, including area code: (781) 547-5900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

o     Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

The disclosure provided under Item 5.02(c) below is incorporated herein by reference.

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

(a) Not applicable.

(b) On July 31, 2007, OXiGENE, Inc. (“OXiGENE” or the “Company”) announced that its Chief Medical Officer, Dr. Peter Harris, has stepped down from his role as the Company's Chief Medical Officer effective as of July 27, 2007. Dr. Harris will be departing from the Company upon execution of his severance agreement. Following a transition period, he will continue to serve as a consultant to the Company.

(c) The Company also announced on July 31, 2007 that Dr. Patricia Ann Walicke has replaced Dr. Peter Harris as the Company’s Chief Medical Officer, effective as of July 27, 2007.

Dr. Patricia Ann Walicke M.D., Ph.D., age 54, has approximately 11 years of pharmaceutical and biotechnology industry experience, specifically in clinical development and regulagtory affairs. Prior to joining OXiGENE, Dr. Walicke was briefly an independent consultant (from April 2007 to July 2007) whose clients included several privately held biotechnology companies. Dr. Walicke was VP of Clinical and Regualtory Affairs at Avidia Inc from October 2005 until October 2006. She remained at Amgen Inc for transition of Avidia’s programs from the time of Avidia’s acquisition in October 2006 until April 2007. Prior to Avidia, Dr. Walicke was the Vice President of Clinical Development at Rinat Neuroscience from October 2003 to October 2005, which subsequently was acquired by Pfizer. From April 1999 until October 2003, Dr Walicke was employed at Genentech, where she held titles of Clinical Scientist, Senior Clinical Scientist and Medical Director. She started her career in industry as a Medical Director at Quintiles, and has also worked at Elan Pharmaceuticals. Prior to working in industry, Dr. Walicke had a neurology practice in Atlanta, Georgia and was a full-time faculty member of the Department of Neurosciences at the University of California, San Diego. Dr. Walicke graduated from MIT with a B.S. in Life Science, from Harvard Medical School with an M.D. and from Harvard Graduate School with a Ph.D.

OXiGENE has entered into an employment agreement (the “Agreement”) with Dr. Walicke with respect to her service as its Vice President and Chief Medical Officer. Pursuant to the Agreement, Dr. Walicke will initially receive an annual base salary of $300,000 per year. In addition, Dr. Walicke may be awarded an annual bonus of 25% of her then-current annual base salary, at the sole discretion of OXiGENE, based on OXiGENE’s assessment of her and OXiGENE’s performance. Dr. Walicke will also receive a signing bonus in the amount of $30,000, subject to repayment in certain events.

Subject to the approval of the Compensation Committee of the Board of Directors, OXiGENE will grant to Dr. Walicke, pursuant to the OXiGENE, Inc. 2005 Stock Plan, options to purchase 200,000 shares of the Company’s common stock at an exercise price equal to the fair market value on the date of grant and OXiGENE’s standard form of option agreement. The options shall vest in equal annual installments over four years beginning on the first anniversary of the grant date. If Dr. Walicke relocates, the Company shall reimburse her for up to $75,000 in relocation expenses, as specified in the Agreement.

Dr. Walicke may terminate the Agreement upon written notice to OXiGENE. OXiGENE may also terminate the Agreement without prior written notice for cause, as defined in the Agreement, as long as, in certain circumstances, it gives Dr. Walicke a minimum period of 30 days to cure the act or omission constituting cause (if reasonably subject to cure), as described in the Agreement. If Dr. Walicke’s employment is terminated by

OXiGENE for cause, or by Dr. Walicke without good reason (as defined in the Agreement), OXiGENE will pay to Dr. Walicke the amount of accrued obligations to Dr. Walicke as of the date of such termination, consisting of accrued and unpaid salary, value of accrued vacation days, amount of unreimbursed and incurred expenses, and the annual bonus related to the most recently completed calendar year, if not already paid.

If Dr. Walicke’s employment is terminated by OXiGENE other than for cause or Dr. Walicke’s disability, OXiGENE will pay to Dr. Walicke the accrued obligations, as described above, an amount equal to 12 months of her then-current base salary (payable on OXiGENE’s normal paydays), and will also pay COBRA premiums, should Dr. Walicke timely elect and be eligible for COBRA coverage, for Dr. Walicke and her immediate family for 12 months (provided that OXiGENE shall have no obligation to provide such coverage if Dr. Walicke becomes eligible for medical and dental coverage with another employer).

If Dr. Walicke’s employment is terminated by OXiGENE (other than for cause or Dr. Walicke’s disability) within one year following a change in control of the Company (as defined in the Agreement), or by Dr. Walicke with good reason within one year following a change in control of the Company, OXiGENE will pay to Dr. Walicke the accrued obligations, as described above, an amount equal to 12 months of her then-current base salary, and will also pay COBRA premiums for a period of 12 months on the same conditions as described above. In addition, all of Dr. Walicke’s unvested equity compensation outstanding on the date of termination shall vest and remain exercisable in accordance with the terms of the applicable plan and the related agreement. Dr. Walicke has also agreed not to engage in activities competitive with the Company during her employment and for a 12 month period following the termination of her employment.

OXiGENE has also entered into a Confidentiality and Inventions Agreement with Dr. Walicke.

(d) Not applicable.

(e) The disclosure provided under Item 5.02(c) above is incorporated herein by reference.

(f) Not applicable.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits:

Exhibit
Number	Description
10.1	Employment Agreement by and among OXiGENE and Dr. Patricia Walicke, dated as of July 27, 2007.
99.1	Press Release dated July 31, 2007.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 1, 2007	OXiGENE, Inc.
	By:	/s/ Richard Chin
		Richard Chin
		Chief Executive Officer

EXHIBITS

Exhibit
Number	Description
10.1	Employment Agreement by and among OXiGENE and Dr. Patricia Walicke, dated as of July 27, 2007.
99.1	Press Release dated July 31, 2007.

EX-10.1

Exhibit 10.1

EMPLOYMENT AGREEMENT

     This employment agreement (the “Agreement”) is entered into as of July 27, 2007 between OXiGENE, Inc., a Delaware corporation (“OXiGENE”), and Patricia Walicke (the “Executive”).

WITNESSETH:

     WHEREAS, OXiGENE and Executive desire to enter into an employment agreement relating to the position of OXiGENE’s Vice President and Chief Medical Officer.

     NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, OXiGENE and Executive hereby agree as follows:

1. Employment

          1.1 Executive shall serve in the capacity of Vice President and Chief Medical Officer, and shall have the duties, responsibilities and authority assigned to Executive by OXiGENE’s President and Chief Executive Officer to whom she shall report.

     Executive, so long as she is employed hereunder, (i) shall devote substantially all of her full professional time and attention to the services required of her as an employee of OXiGENE, except as otherwise agreed and except as permitted in accordance with paid vacation time subject to OXiGENE’s existing vacation policy, and subject to OXiGENE’s existing policies pertaining to reasonable periods of absence due to sickness, personal injury or other disability, (ii) shall use her best efforts to promote the interests of OXiGENE, and (iii) shall discharge her responsibilities in a diligent and faithful manner, consistent with sound business practices. Notwithstanding the above, the Executive may continue to serve as a consultant / advisor for the entities listed on Exhibit A provided that such service does not create any conflicts, ethical or otherwise, with Executive’s responsibilities to OXiGENE and further provided that Executive’s time commitments do not unreasonably interfere with her fulfillment of her responsibilities hereunder, as determined by OXiGENE.

2. Term

     The term of Executive’s employment under this Agreement shall commence at a date mutually agreed upon by the parties and shall continue until terminated by either party in accordance with Section 6 hereof (the “Employment Term”).

3. Base Salary; Stock Options, Sign-on Bonus

          3.1 During the Employment Term, Executive initially shall be paid an annual base salary in the amount of $300,000 (such amount as adjusted, from time to time, the “Base Salary”), payable in biweekly (26) installments in accordance with OXiGENE’s

payroll schedule from time to time in effect. The Base Salary will be subject to review annually or on such periodic basis (not to exceed annually) as OXiGENE reviews the compensation of OXiGENE’s other senior executives and may be adjusted upwards in the sole discretion of the Board of Directors of OXiGENE (the “Board”) or its designee. Executive will be eligible during each year of the Employment Term for consideration for annual bonus (the “Annual Bonus”) equal to 25% of her then-current Base Salary, based upon OXiGENE’s assessment of the performance of Executive and OXiGENE at the sole discretion of OXiGENE, to be paid prior to March 15th of the year following the year in which the Annual Bonus is earned. The Annual Bonus is based on the achievement of individual and Company written goals established on an annual basis and on overall Company performance. Executive shall be eligible for a pro-rated Annual Bonus for 2007. The Board may in its discretion award Executive a more generous bonus.

OXiGENE shall grant to Executive, subject to approval by the Compensation Committee of the Board, options to purchase 200,000 shares of OXiGENE’s common stock at an exercise price equal to the fair market value of such stock on the date of grant pursuant to and in accordance with the terms of OXiGENE’s 2005 Stock Plan (the “Stock Plan”) and OXiGENE’s standard form of option agreement within 60 days of Executive’s first day of employment. To the extent allowed by law, the options shall be treated as incentive options. The options shall vest in four equal annual increments over the four (4) year period measured from the date of grant of such options, with vesting to begin on the one (1) year anniversary of the grant date. In addition, Executive shall be eligible to receive stock option grants, stock bonuses, restricted stock grants or other equity compensation awards granted to Executive from time to time by the Board in its sole discretion and to participate in any equity compensation plan that may be established by OXiGENE for Executive or its executive team generally.

Executive shall earn a $30,000 signing bonus, payable on the first payroll following the first day of employment. If Executive’s employment hereunder is terminated either by OXiGENE for Cause or voluntarily by Executive in the absence of a Good Reason (as defined in Section 6.6) within one (1) year of the Commencement Date, Executive will promptly repay a portion of the Commencement Bonus equal to the amount of the Commencement Bonus, net of applicable taxes and deductions, multiplied by a fraction, the numerator of which equals the number of days from the effective date of such termination to the first anniversary of the Commencement Date and the denominator of which will be 365 (or OXiGENE may withhold such amount from any payments otherwise due to Executive).

4. Benefits

     Executive shall be entitled to participate in employee benefit plans and arrangements made available by OXiGENE generally to OXiGENE employees of comparable rank during the Employment Term.

5. Business Expenses

          5.1 The Executive shall be entitled to receive an American Express Corporate Card (or other card should OXiGENE change to another card issuer), for business related expenses and prompt reimbursement will be made for all reasonable and customary expenses incurred by her in performing services hereunder during the Employment Term; provided that such expenses are incurred and accounted for in accordance with the policies and procedures established by OXiGENE.

          5.2 If the Executive relocate as result of business needs and at the request of the Company, the Company shall reimburse Employee for up to $75,000 for Relocation Expenses (as defined below) relating to such relocation so long as the Employee is employed by the Company at the time of the relocation. Such reimbursement shall be made provided that such expenses are incurred and accounted for in accordance with the policies and procedures established by OXiGENE. “Relocation Expenses” shall mean reasonable expenses incurred by the Employee related to costs of the physical movement of all goods and vehicles that are in Employee’s California home, up to three round trip airfares and hotel accommodations for “house hunting” and up to three months of temporary housing.

6. Termination

          6.1 The Executive may resign from employment with OXiGENE upon written notice to OXiGENE.

          6.2 If the Executive’s employment is terminated by OXiGENE other than for Cause (as defined below) or the Executive’s disability, then OXiGENE shall provide to Executive the following termination compensation:

(a)	payments equal to Executive’s then-current Base Salary for a period of twelve (12) months, payable on OXiGENE’s normal paydays.
(b)	a payment equal to the portion of the Executive’s Base Salary that has accrued prior to any termination of the Executive’s employment with OXiGENE that has not yet been paid;
(c)	to the extent required by law and OXiGENE’s policy, an amount equal to the value of the Executive’s accrued but unused vacation days;
(d)	the amount of any expenses properly incurred by the Executive on behalf of OXiGENE prior to any termination and not yet reimbursed;
(e)	the Annual Bonus related to the most recently completed calendar year, if not already paid, and

(f) should Executive timely elect and be eligible for COBRA coverage, payment of Executive’s COBRA premiums for the Executive and the Executive’s immediate family’s medical and dental insurance coverage for a period of twelve (12) months; provided, that OXiGENE shall have no obligation to provide such coverage if Executive becomes eligible for medical and dental coverage with another employer. Executive shall give prompt written notice to the Company on attaining such eligibility.

     Notwithstanding anything to the contrary herein, OXiGENE’s obligation to provide the termination compensation described in this Section 6.2 (except for pursuant to (b), (c), (d) and (e)) shall be conditional upon the Executive delivering to OXiGENE, and not thereafter revoking, a fully executed general release, in a form satisfactory to OXiGENE, of all claims against OXiGENE, its affiliates, and each of their officers, directors, employees, agents and attorneys. Such payments described in Sections 6.2(a),, (e) and (f), unless otherwise required by law, shall become due on the first payday which is at least ten (10) business days after the Executive delivers to OXiGENE said release.

          6.3 If, following any Change in Control (as such term is defined below) and prior to the expiration of one (1) year from the date of such Change in Control, (1) Executive’s employment is terminated (other than for Cause or the Executive’s disability) or (2) in the event of a termination with Good Reason, then

(a) The Executive shall receive, as soon as practicable after the termination date:

(i) An amount equal to twelve (12) months of Executive’s then current Base Salary; and

(ii) the termination compensation described in Sections 6.2(b), (c), (d), (e) and (f) above.

(b) All stock options, stock appreciation rights, restricted stock, and other incentive compensation granted to the Executive by OXiGENE shall vest and be immediately exercisable. Executive may exercise all such vested options and rights, and shall receive payments and distributions accordingly

“Change in Control” shall mean the occurrence of any of the following events:

(i) Ownership. Any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of OXiGENE representing 50% or more of the total voting power represented by OXiGENE’s then outstanding voting securities (excluding for this purpose any such voting securities held by OXiGENE or its affiliates or by any employee benefit plan of OXiGENE)

pursuant to a transaction or a series of related transaction which the Board of Directors does not approve; or

(ii) Merger/Sale of Assets. (A) A merger or consolidation of OXiGENE whether or not approved by the Board of Directors, other than a merger or consolidation which would result in the voting securities of OXiGENE outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least 50% of the total voting power represented by the voting securities of OXiGENE or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (B) the stockholders of OXiGENE approve an agreement for the sale or disposition by OXiGENE of all or substantially all of OXiGENE’s assets; or

(iii) Change in Board Composition. A change in the composition of the Board of Directors, as a result of which fewer than a majority of the directors are Incumbent Directors. “Incumbent Directors” shall mean directors who either (A) are directors of OXiGENE as of the date of this Agreement, or (B) are elected, or nominated for election, to the Board of Directors with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but shall not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to OXiGENE).

          6.4 Except as otherwise set forth in this Section 6 or as required by applicable law, all obligations of OXiGENE under this Agreement shall cease if, during the Employment Term, OXiGENE terminates Executive for Cause or the Executive resigns her employment for other than Good Reason. Upon such termination, Executive shall be entitled to receive only the termination compensation described under Sections 6.2(b), (c), (d) and (e).

          6.5 For the purposes of this Agreement, the term “Cause” shall mean any of the following:

(a)	the Executive’s substantial failure to perform any of her duties hereunder or to follow reasonable, lawful directions of the Board or any officer to whom the Executive reports;
(b)	the Executive’s willful misconduct or willful malfeasance in connection with her employment;
(c)	the Executive’s conviction of, or plea of nolo contendere to, any crime constituting a felony under the laws of the United States or any state thereof, or any other crime involving moral turpitude;
(d)	the Executive’s material breach of any of the provisions of this Agreement, OXiGENE’s bylaws or any other agreement with OXiGENE; or

(e)	the Executive’s engaging in misconduct which has caused significant injury to OXiGENE, financial or otherwise, or to OXiGENE’s reputation; or
(f)	any act, omission or circumstance constituting cause under the law governing this Agreement.

     If Cause arises under Section 6.5(a), (b), (d), (e), or (f) the Executive shall be given a minimum period of thirty (30) days to reasonably cure such Cause (if reasonably subject to cure).

          6.6 For the purposes of this Agreement, “Good Reason” shall mean: (i) without the Executive’s express written consent, any material reduction in Executive’s title, or responsibilities compared to those prior to a Change in Control (as such term is defined in Section 6.3); (ii) relocation of more than 60 miles; (iii) without the Executive’s express written consent, a material reduction by OXiGENE in the Executive’s total compensation as in effect on the date hereof or as the same may be increased from time to time, provided that it shall not be deemed a material reduction if (a) the amount of Executive’s Annual Bonus is less than the amount of any previously awarded Annual Bonuses or (b) a benefit is amended and such amendment affects all eligible executive participants; or (iv) the Company OXiGENE breaches a material term of this Agreement and such breach has remained uncured for a minimum of thirty (30) days after Executive has notified OXiGENE of breach. To be effective, such notice must be in writing and set forth the specific alleged Good Reason for termination and the factual basis supporting the alleged Good Reason.

          6.7 The foregoing payments upon Executive’s termination shall constitute the exclusive payments due Executive upon termination of her employment with OXiGENE under this Agreement or otherwise, provided, however that except as stated above, such payments shall have no effect on any benefits which may be payable to Executive under any plan of OXiGENE which provides benefits after termination of employment.

7 Taxes.

     Any amounts or benefits payable or provided to the Executive hereunder shall be paid or provided to the Executive subject to all applicable taxes required to be withheld by OXiGENE pursuant to national and/or local law. The Executive shall be solely responsible for all taxes imposed on the Executive by reason of her receipt of any amounts of compensation or benefits payable hereunder and OXiGENE makes no representation, warranty or promise regarding the tax treatment of any payment or benefit provided to the Executive.

8 Non-Competition / Non-Solicitation

          8.1`While the Executive is employed by OXiGENE and for a period of 12 months following the termination of her employment (the “Noncompetition Period”), the Executive shall not, for herself or on behalf of any other person or

entity, directly or indirectly, whether as principal, partner, agent, independent contractor, stockholder, employee, consultant, representative or in any other capacity, own, manage, operate or control, be concerned or connected with, or employed by, engage in or have a financial interest in any Restricted Business (as defined in Section 8.3) anywhere in the world (the “Restricted Territory”) except that nothing in this Agreement shall preclude the Executive from purchasing or owning securities of any such business if such securities are publicly traded, and provided that the Executive’s holdings do not exceed two (2%) percent of the issued and outstanding securities of any class of securities of such business.

          8.2 In addition, during the Noncompetition Period the Executive shall not, either individually or on behalf of or through any third party, solicit, divert or appropriate or attempt to solicit, divert or appropriate, for the purpose of competing with OXiGENE or any present or future parent, subsidiary or other affiliate of OXiGENE which is engaged in the Restricted Business, any customers, clients or vendors of OXiGENE with whom the Executive has had significant contact or to whom the Executive has provided services during the Executive’s last two years of employment with OXiGENE.

          8.3 For the purposes of this Agreement, the term “Restricted Business” shall mean any person, partnership, corporation, business organization or other entity (or a division or business unit of any entity) whose primary business is the research, development, manufacture, marketing or selling of products or services that are the same as or similar to those that OXiGENE is researching, developing, manufacturing, marketing or selling during the Executive’s employment with OXiGENE, provided that (i) after the Executive’s employment with OXiGENE has terminated, this definition shall apply only with respect to products and services that are the same as or similar to those that OXiGENE was engaged in or developing during the last two (2) years of her employment with OXiGENE; (ii) nothing in this definition shall operate to prevent Executive from working for or with respect to any subsidiary, division or affiliate (each, a “Unit”) of an entity if that Unit is not itself a Restricted Business, irrespective of whether some other Unit of such entity constitutes a Restricted Business (as long as the Executive does not provide any services for such other Unit); and (iii) Restricted Business will not include researching, developing, manufacturing, marketing or selling products or services other than those specific products (vascular disrupting agents) being researched, developed, manufactured, marketed, or sold by or on behalf of OXiGENE when the Executive’s employment with OXiGENE terminates.

          8.4 During the Non-Competition Period, neither the Executive nor any Executive-Controlled Person (as defined below) will, without the prior written consent of the Board, directly or indirectly solicit for employment, or make an unsolicited recommendation to any other person that it employ or solicit for employment any person who is or was, at any time during the 9 month period prior to the terminations date, an officer, Executive or key employee of OXiGENE or any affiliate of OXiGENE. As used in this Agreement, the term “Executive-Controlled Person” shall mean any company, partnership, firm or other entity as to which Executive possesses, directly or indirectly,

the power to direct or cause the direction of the management and policies of such entity, whether through the ownership of voting securities, by contract or otherwise.

          8.5 The provisions contained in this Section 8 as to the time periods, scope of activities, persons or entities affected, and territories restricted shall be deemed divisible so that, if any provision contained in this Section 8 is determined to be invalid or unenforceable, such provisions shall be deemed modified so as to be valid and enforceable to the full extent lawfully permitted.

          8.6 Executive agrees that the provisions of this Section 8 are reasonable and necessary for the protection of OXiGENE and that they may not be adequately enforced by an action for damages and that, in the event of a material breach thereof by Executive or any Executive-Controlled Person, OXiGENE shall be entitled to apply for and obtain injunctive relief in any court of competent jurisdiction to restrain the breach or threatened breach of such violation or otherwise to enforce specifically such provisions against such violation, without the necessity of the posting of any bond by OXiGENE. Executive further covenants under this Section 8, that OXiGENE shall be entitled to an accounting and repayment of all profits, compensation, commissions, remuneration or other benefits that Executive directly or indirectly has realized and/or may realize as a result of, growing out of or in connection with any such violation. Such a remedy shall, however, be cumulative and not exclusive and shall be in addition to any injunctive relief or other legal equitable remedy to which OXiGENE is or may be entitled

9 Indemnification

     OXiGENE, to the extent permitted by its Articles and By Laws, shall indemnify the Executive for all claims, losses, expenses, costs, obligations, and liabilities of every nature whatsoever incurred by the Executive to any third party as a result of the Executive’s acts or omissions as an employee of OXiGENE, but excluding from such indemnification any claims, losses, expenses, costs, obligations, or liabilities incurred by the Executive as a result of the Executive’s bad faith, willful misconduct or gross negligence.

10 Attorney’s Fees and Expenses

     OXiGENE and the Executive agree that in the event of litigation arising out of or relating to this Agreement, the prevailing party shall be entitled to reimbursement from the other party to the prevailing party’s reasonable attorney fees and expenses.

11 Amendments

     This Agreement may not be altered, modified or amended except by a written instrument signed by each of the parties hereto.

12 Assignments

     Neither this Agreement nor any of the rights or obligations hereunder shall be assigned or delegated by any party hereto without the prior written consent of the other party; provided, however, that any payments and benefits owed to Executive under this Agreement shall inure to the benefit of her heirs and personal representatives.

13 Waiver

     Waiver by any party hereto of any breach or default by any other party of any of the terms of this Agreement shall not operate as a waiver of any other breach or default, whether similar to or different from the breach or default waived.

14 Severability

     In the event that any one or more of the provisions of this Agreement shall be or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not be affected thereby.

15 Notices

     All notices and other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given when personally delivered or when mailed by registered mail, return receipt requested, postage prepaid, addressed as follows:

     If to Executive, to her as follows:

     If to OXiGENE, to it as follows:

OXiGENE, Inc.
230 Third Avenue
Waltham, MA 02451
Attn: Richard Chin or his successor

Or to such other address or such other person as Executive or OXiGENE shall designate in writing in accordance with this Section 15, except that notices regarding changes in notices shall be effective only upon receipt.

16 Headings

     Headings to Sections in this Agreement are for the convenience of the parties only and are not intended to be a part of, or to affect the meaning or interpretation of, this Agreement.

17 Governing Law; Venue; Jury Waiver

     This Agreement shall be governed by the laws of the Commonwealth of Massachusetts without reference to the principles of conflict of laws. Each of the parties hereto consents to the jurisdiction of the federal and state courts of the Commonwealth of Massachusetts in connection with any claim or controversy arising out of or connected with this Agreement, and said courts shall be the exclusive fora for the resolution of any such claim or controversy. Service of process in any such proceeding may be made upon each of the parties hereto at the address of such party as determined in accordance with Section 15 of this Agreement, subject to the applicable rules of the court in which such action is brought. Both the Executive and OXiGENE waive any right they may have to a trial by jury and agree that any dispute between them arising from or relating to the Agreement or the Executive’s employment shall be tried by a judge sitting without a jury.

18 All Other Agreements Superseded.

     Except for Executive’s Confidentiality and Inventions Agreement, which the Executive shall sign as a condition of her employment and of the effectiveness of this Agreement, this Agreement contains the entire agreement between Executive and OXiGENE with respect to all matters relating to Executive’s employment with OXiGENE and, as of the date hereof, will supersede and replace any other agreements, written or oral, between the parties relating to the terms or conditions of Executive’s employment with OXiGENE.

     IN WITNESS WHEREOF, OXiGENE and Executive have caused this Agreement to be executed as of the date first above written.

/s/ Patricia Walicke
Patricia Walicke
July 31, 2007 Start Date
OXiGENE, Inc.
By:	/s/ Richard Chin
	Name:	Richard Chin
	Title:	President & CEO

Exhibit A

VLST (Viral Logic Systems Technology), consultant
Barofold, consultant and Clinical Advisory Board member
SARCode, consultant and Clinical Advisory Board member
TPG Ventures, consultant
Essex Woodlands Health Ventures, consultant
Peptimmune, consultant
Kalobios, consultant

Spinal Muscular Atrophy Foundation, consultant
Retts Syndrome Foundation, consultant

EX-99.1

CONTACT: OXiGENE, Inc.
Shari Annes, 650-888-0902
Investor Relations, 781-547-5900

OXiGENE Appoints Patricia Walicke, M.D., Ph.D. as Chief Medical Officer
Drug Development Veteran to Oversee Clinical Development

WALTHAM, Mass. — July 31, 2007— OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, has named Patricia Walicke, M.D., Ph.D., as Chief Medical Officer and Vice President.

“Dr. Walicke’s scientific expertise and extensive drug development experience span the entire drug development process, from IND filings, translational medicine, and Phase I work, through Phase II and III studies and approval,” said Richard Chin, M.D., President and Chief Executive Officer of OXiGENE. “Dr. Walicke will be a tremendous asset to OXiGENE as we continue to advance our drug development programs.”

“Vascular disrupting agents address a common pathophysiologic mechanism and therefore have the potential to help people with a variety of diseases. I am excited to build upon the strong foundation of basic and clinical research already established at OXiGENE, and to work with the company’s talented team,” said Dr. Walicke.

Most recently, Dr. Walicke served as Vice President, Clinical and Regulatory Affairs at Avidia, Inc., a subsidiary of Amgen, where she was responsible for development of an IL-6 inhibitor based on a novel protein technology. Prior to Avidia, Dr. Walicke served as Vice-President, Clinical Development at Rinat Neurosciences, focusing on translational medicine for an anti-NGF antibody for pain and an anti-beta amyloid antibody for Alzheimer’s disease. Avidia and Rinat Neurosciences were initially privately-held companies which were acquired by Amgen Corporation and Pfizer, Inc, respectively. Prior to Rinat, she served in clinical development roles at Genentech, where she played a key role in the successful development and registration of Raptiva^® and in the initiation of the Rituxan^® program for multiple sclerosis. Her experience also includes work on the multiple sclerosis drug, Tysabri^®, while serving as Director, Clinical and Regulatory Affairs at Athena Neurosciences, and provision of clinical research services while serving as Director, Medical and Scientific Services at Quintiles Pacific, Inc. Dr. Walicke has held full-time and adjunct academic appointments at leading medical research institutions and is a board certified neurologist. She earned her B.S. degree from the Massachusetts Institute of Technology, her M.D. from Harvard Medical School, and her Ph.D. from Harvard University. Dr. Walicke is an inventor on two patents and an author on over 90 articles, book chapters and abstracts.

Concurrent with Dr. Walicke’s appointment, Dr. Peter Harris will step down from his role as the company’s Chief Medical Officer. Following a transition period, he will continue to actively serve as a consultant to the company.

- more -

“Peter has made innumerable contributions to the company. Most notably, he oversaw the design and initiation of the ZYBRESTAT™ pivotal registration study and led the team that secured the Special Protocol Assessment for the ZYBRESTAT pivotal study from the FDA,” said Dr. Chin. “We look forward to Peter’s continued contribution to the company as a consultant.”

About OXiGENE, Inc.

OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company’s major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

Safe Harbor Statement

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, including with respect to the timing and results of its clinical trials involving ZYBRESTAT and OXi4503, may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE’s reports to the Securities and Exchange Commission, including OXiGENE’s Form 10-Q, 8-K and 10-K reports. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2006 for a description of these risks.

# # #